Evidence map›Paper›PMID 41271518›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026

Dietary tributyrin supplementation in Parkinson's disease: An open-label target engagement study.

Jeffrey L B Bohnen, Stiven Roytman, Travis P Wigstrom, Robert K Vangel, Jaime E Barr, Giulia Carli, Sean M Parks, Hitasha Mittal, Claire Martino, Prabesh Kanel and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Gut-Brain Signaling in Parkinson's Disease: A Narrative Review.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jeffrey L B BohnenMichigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA; Department of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA; University of Michigan Medical School, Ann Arbor, MI, 48109, USA; Department of Psychiatry, University of Michigan, Ann Arbor, MI, 48109, USA. Electronic address: jbohnen@umich.edu.
Stiven RoytmanDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
Travis P WigstromDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA; University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Robert K VangelDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
Jaime E BarrDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
Giulia CarliDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
Sean M ParksUniversity of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Hitasha MittalDepartment of Medicine and Surgery, Universita Vita Salute San Raffaele, 20132, Milan, Italy.
Claire MartinoCollege of Literature, Science, and the Arts, University of Michigan, Ann Arbor, MI, 48109, USA.
Prabesh KanelDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA; Department of Radiology, University of Michigan, Ann Arbor, MI, 48109, USA.
Roger L AlbinMichigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA; Department of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA; University of Michigan Medical School, Ann Arbor, MI, 48109, USA; Morris K. Udall Center of Excellence for Parkinson's Disease Research, University of Michigan, Ann Arbor, MI, 48109, USA; Parkinson's Foundation Research Center of Excellence, University of Michigan, Ann Arbor, MI, 48109, USA; Department of Radiology, University of Michigan, Ann Arbor, MI, 48109, USA.
Nicolaas I BohnenMichigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA; Department of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA; University of Michigan Medical School, Ann Arbor, MI, 48109, USA; Neurology Service and Geriatric Research, Education, and Clinical Center, VA Ann Arbor Healthcare System, Ann Arbor, MI, 48105, USA; Morris K. Udall Center of Excellence for Parkinson's Disease Research, University of Michigan, Ann Arbor, MI, 48109, USA; Parkinson's Foundation Research Center of Excellence, University of Michigan, Ann Arbor, MI, 48109, USA; Department of Radiology, University of Michigan, Ann Arbor, MI, 48109, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Short-chain fatty acids such as butyrate (key signaling molecules that influence the gut-brain axis and modulate inflammatory, mitochondrial, and transcriptional regulatory processes) are attracting interest as potential treatments for neurodegenerative disorders such as Parkinson's disease. Oral butyrate supplementation in the form of sodium butyrate suffers from limitations, however, as butyrate is rapidly metabolized by colonocytes, resulting in low plasma and brain concentrations. The butyrate prodrug tributyrin, naturally present in butter, is a neutral short-chain fatty acid triglyceride likely to overcome the pharmacokinetic drawbacks of butyrate. Despite these pharmacokinetic advantages, no clinical studies to date have assessed the safety, tolerability, and target engagement of tributyrin as a postbiotic treatment in the setting of Parkinson's disease. Tributyrin's safety profile and potential biomechanistic effects were thus investigated in the setting of Parkinson's disease via an open-label target engagement study. Fourteen individuals with Parkinson's disease and three normal controls completed a 30-day (±7 days) intervention of dietary tributyrin supplementation (500 ​mg taken orally three times daily), demonstrating a reassuring safety profile with high rates of adherence. Ten subjects completed [

Indexed as

Dietary SupplementsParkinson DiseaseTriglyceridesAgedBrainFemaleHumansMaleMiddle AgedtributyrinTriglyceridesButyrateGut-brain axisNeuroimagingParkinson’s diseasePostbiotic interventionTributyrin

Identifiers

PMID41271518
PMCPMC12976542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.